Chemoprevention Of Lung Cancer: Diagnosis And Management Of Lung Cancer

Publication Date: May 1, 2013
Last Updated: March 14, 2022

Recommendations

Agents Tested in Chemoprevention Trials (With Lung Cancer as an End Point)

For individuals with a greater than 20 pack year history of smoking or with a history of lung cancer, the use of β carotene supplementation is not recommended for primary, secondary, or tertiary chemoprevention of lung cancer. (1, A)
307795
For individuals at risk for lung cancer and for patients with a history of lung cancer, the use of vitamin E, retinoids, and N-acetylcysteine and isotretinoin is not recommended for primary, secondary, or tertiary prevention of lung cancer. (1, A)
307795
For individuals at risk for lung cancer and for patients with a history of lung cancer, the use of aspirin is not recommended for primary, secondary, or tertiary prevention of lung cancer (outside of the setting of a well-designed clinical trial). (2, B)
307795
In individuals with a history of early stage NSCLC, the use of selenium as a tertiary chemopreventive agent of lung cancer is not recommended. (1, B)
307795

Agents Tested in Intermediate End Point Biomarker Trials

For individuals at risk for lung cancer or with a history of lung cancer, PGI 2 analogs (iloprost), COX-2 inhibitors (celecoxib), and anethole dithiolethione, are not recommended for use for primary, secondary, or tertiary lung cancer chemoprevention (outside of the setting of a well-designed clinical trial). (1, B)
307795
For individuals at risk for lung cancer or with a history of lung cancer, inhaled steroids are not recommended for use for primary, secondary, or tertiary lung cancer chemoprevention (outside of the setting of a well-designed clinical trial). (1, B)
307795

Additional Targeted Pathways/Future Directions

For individuals at risk for lung cancer or with a history of lung cancer, the use of pioglitazone or myoinositol, for primary, secondary, or tertiary lung cancer chemoprevention is not recommended (outside of the setting of a well-designed clinical trial). (1, B)
307795
In individuals at risk for lung cancer, the use of tea extract, or metformin is not suggested for primary, secondary or tertiary prevention of lung cancer (outside of the setting of a well-designed clinical trial). (2, C)
307795

Recommendation Grading

Overview

Title

Chemoprevention Of Lung Cancer: Diagnosis And Management Of Lung Cancer

Authoring Organization

Publication Month/Year

May 1, 2013

Last Updated Month/Year

January 9, 2024

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Document Objectives

Lung cancer is the most common cause of cancer death in men and women in the United States. Cigarette smoking is the main risk factor. Former smokers are at a substantially increased risk of developing lung cancer compared with lifetime never smokers. Chemoprevention refers to the use of specific agents to reverse, suppress, or prevent the process of carcinogenesis. This article reviews the major agents that have been studied for chemoprevention.

Target Patient Population

For individuals at risk for lung cancer

Inclusion Criteria

Female, Male, Adolescent, Adult, Older adult

Health Care Settings

Ambulatory, Outpatient

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Prevention, Management

Diseases/Conditions (MeSH)

D011315 - Preventive Medicine, D008175 - Lung Neoplasms, D018890 - Chemoprevention

Keywords

lung cancer, chemoprevention, carcinogen

Supplemental Methodology Resources

Data Supplement